RU2005101621A - Антитела и их применения - Google Patents

Антитела и их применения Download PDF

Info

Publication number
RU2005101621A
RU2005101621A RU2005101621/13A RU2005101621A RU2005101621A RU 2005101621 A RU2005101621 A RU 2005101621A RU 2005101621/13 A RU2005101621/13 A RU 2005101621/13A RU 2005101621 A RU2005101621 A RU 2005101621A RU 2005101621 A RU2005101621 A RU 2005101621A
Authority
RU
Russia
Prior art keywords
antibody
patient
antibody fragment
cell
agent
Prior art date
Application number
RU2005101621/13A
Other languages
English (en)
Russian (ru)
Inventor
Авигдор ЛЕВАНОН (IL)
Авигдор ЛЕВАНОН
Рахель БЕН-ЛЕВИ (IL)
Рахель БЕН-ЛЕВИ
Даниэль ПЛАКСИН (IL)
Даниэль ПЛАКСИН
Эстер СЗАНТОН (IL)
Эстер СЗАНТОН
Йошевед ХАГАЙ (IL)
Йошевед ХАГАЙ
МАР-ЧАЙМ Хагит ХОЧ (IL)
МАР-ЧАЙМ Хагит ХОЧ
Original Assignee
Савиент Фармасьютикалс, Инк. (Us)
Савиент Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Савиент Фармасьютикалс, Инк. (Us), Савиент Фармасьютикалс, Инк. filed Critical Савиент Фармасьютикалс, Инк. (Us)
Publication of RU2005101621A publication Critical patent/RU2005101621A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
RU2005101621/13A 2002-07-01 2003-06-30 Антитела и их применения RU2005101621A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01
US10/189032 2002-07-01

Publications (1)

Publication Number Publication Date
RU2005101621A true RU2005101621A (ru) 2005-11-20

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005101621/13A RU2005101621A (ru) 2002-07-01 2003-06-30 Антитела и их применения

Country Status (12)

Country Link
EP (1) EP1534332A4 (zh)
JP (1) JP2005536199A (zh)
KR (1) KR20060011925A (zh)
CN (1) CN1678347A (zh)
AU (1) AU2003263764A1 (zh)
BR (1) BR0312483A (zh)
CA (1) CA2491363A1 (zh)
IL (1) IL166063A0 (zh)
MX (1) MXPA05000272A (zh)
PL (1) PL374439A1 (zh)
RU (1) RU2005101621A (zh)
WO (1) WO2004003166A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
TWI454274B (zh) * 2004-05-11 2014-10-01 Abgenomics Cooperatief Ua Ｔ細胞之死亡誘導表位
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
JP6069209B2 (ja) 2010-11-12 2017-02-01 ジェンティウム ソシエタ ア レスポンサビリタ リミタータ 移植片対宿主病（ｇｖｈｄ）の予防および／または治療に使用するためのデフィブロタイド
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CN104619857A (zh) 2012-06-22 2015-05-13 真蒂奥姆有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
KR101896751B1 (ko) * 2015-12-01 2018-10-04 주식회사 엘지화학 열가소성 수지, 이의 제조방법 및 이를 포함하는 열가소성 수지 조성물
CA3106418A1 (en) * 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
CN111715409B (zh) * 2020-07-01 2021-07-23 中南大学 一种微细粒方铅矿的组合铅抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914957A (pt) * 1998-10-30 2001-07-24 Genetics Inst Inibição de células t citotóxicas por antagonistas de ligando de selectina-p (psgl)
PL362227A1 (en) * 2000-03-24 2004-10-18 Genetic Institute, Llc A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Also Published As

Publication number Publication date
CA2491363A1 (en) 2004-01-08
BR0312483A (pt) 2005-08-09
KR20060011925A (ko) 2006-02-06
EP1534332A4 (en) 2006-11-22
JP2005536199A (ja) 2005-12-02
MXPA05000272A (es) 2005-09-20
IL166063A0 (en) 2006-01-15
EP1534332A2 (en) 2005-06-01
WO2004003166A2 (en) 2004-01-08
AU2003263764A1 (en) 2004-01-19
CN1678347A (zh) 2005-10-05
WO2004003166A3 (en) 2005-03-10
PL374439A1 (en) 2005-10-17

Similar Documents

Publication Publication Date Title
FI102355B (fi) Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
RU2005101621A (ru) Антитела и их применения
Gredičak et al. Enediyne compounds- new promises in anticancer therapy
UA119167C2 (uk) Біспецифічне антитіло, яке зв'язується з cd38 та cd3
IE76467B1 (en) New linker for bioactive agents
JP2000503639A (ja) 分枝ヒドラゾンのリンカー類
MXPA05004712A (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos.
JP2010508043A (ja) 抗体産生を改善するための方法
NL8302586A (nl) Derivaten van morfolinyl daunorubicine en morfolinyl doxorubicine alsmede analogen daarvan.
EP0398305B1 (en) Anthracycline conjugates having a novel linker and methods for their production
WO2005049082A2 (en) Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia
RU2003123101A (ru) Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование
RU2003123100A (ru) Специфические антитела человека для селективной терапии рака
RU2005101622A (ru) Композиции и способы терапевтического лечения
US20040202665A1 (en) Compositions and methods for therapeutic treatment
RU2006102571A (ru) Специфические антитела человека
EP0490434B1 (en) Labelled, modified oligonucleotides
Mujoo et al. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin
WO2023275112A1 (en) Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
CN115177751A (zh) 缀合物、其制备方法和用途
Foss et al. Experimental therapies in the treatment of cutaneous T-cell lymphoma
KR20210116861A (ko) 압타머기반 입자 및 이의 제조방법
Kondo et al. Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts
CA2010164C (en) Anthracycline immunoconjugates having a novel linker and methods for their production
Mathé et al. Second-Generation Anthracyclines

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070913